SCHEMBL1916945

SCHEMBL1916945

COc1cnc(Cl)nc1NCCNC(C)=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.51
HSD17B10 Q99714 4/20 0.51
CYP2C19 P33261 4/20 0.51
ALOX15 P16050 3/20 0.51
CYP1A2 P05177 6/20 0.46
CYP2D6 P10635 5/20 0.46
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
STK17A Q9UEE5 2/20 0.44
STK17B O94768 1/20 0.44
GLP1R P43220 1/20 0.43
TSHR P16473 3/20 0.43
CLK4 Q9HAZ1 3/20 0.43
MTNR1A P48039 5/20 0.43
MTNR1B P49286 5/20 0.43
P2RX3 P56373 1/20 0.42
P2RX2 Q9UBL9 1/20 0.42
SUV39H2 Q9H5I1 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3284910 0.86 STK17B (0.42) CYP3A4HSD17B10CYP2C19ALOX15CYP1A2
SCHEMBL1916893 0.86 STK17B (0.42) CYP3A4HSD17B10CYP2C19ALOX15CYP1A2
SCHEMBL3310812 0.83 STK17B (0.57) CYP3A4HSD17B10CYP2C19ALOX15CYP1A2
SCHEMBL1916915 0.82 CYP3A4 (0.48) CYP3A4HSD17B10CYP2C19ALOX15CYP1A2
SCHEMBL25902572 0.81 HTT (0.58) ALDH1A1KDM4ESTK17ASTK17BTSHR
SCHEMBL13177678 0.81 GLP1R (0.45) CYP3A4HSD17B10CYP2C19ALOX15CYP1A2
SCHEMBL2816596 0.81 GLP1R (0.45) CYP3A4HSD17B10CYP2C19ALOX15CYP1A2
SCHEMBL1774178 0.81 GLP1R (0.45) CYP3A4HSD17B10CYP2C19ALOX15CYP1A2
SCHEMBL23924759 0.80 EGFR (0.46) CYP1A2ALDH1A1KDM4ETSHR
SCHEMBL1916465 0.80 GLP1R (0.44) CYP3A4HSD17B10CYP2C19ALOX15CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420630-B2 Pyrimidine derivatives BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2013-04-16 US disclosed
EP-2090571-B1 Pyrimidine derivates, medicaments comprising them, their use and process of their preparation BOEHRINGER INGELHEIM PHARMA (DE) 2012-05-16 EP disclosed
EP-2332924-A1 Pyrimidine derivates, medicaments comprising them, their use and process of their preparation Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2011-06-15 EP disclosed
US-20100152167-A1 PYRIMIDINE DERIVATIVES BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-06-17 US disclosed
US-7709480-B2 Pyrimidine derivatives BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-05-04 US disclosed
EP-2090571-A1 Pyrimidine derivates, medicaments comprising them, their use and process of their preparation Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2009-08-19 EP disclosed
US-7173028-B2 Pyrimidine derivatives BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-02-06 US disclosed
US-20060100211-A1 Pyrimidine derivatives BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-05-11 US disclosed
EP-1438053-A1 PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-07-21 EP disclosed
US-20030171359-A1 Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-09-11 US disclosed
WO-2003032997-A1 PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100211-A1 Pyrimidine derivatives TYMP, TYMS, DPYD CYP3A4 721/4885HSD17B10 2984/4885CYP2C19 264/4885
US-20030171359-A1 Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases COL1A1, MKI67, INSR CYP3A4 885/4885HSD17B10 3864/4885CYP2C19 242/4885
US-20100152167-A1 PYRIMIDINE DERIVATIVES TYMP, TYMS, DPYD CYP3A4 721/4885HSD17B10 2984/4885CYP2C19 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.